Get started
Author

Nihan Küçük

Observed names: KÜÇÜK YILMAZ, NİHAN, Nihan Kucuk, Nihan Kucuk Yilmaz, Nihan KÜÇÜK, Nihan Küçük Yılmaz
Institution: Yalova University
ORCID: 0000-0002-9205-1467
Observed ORCID: 0000-0002-9205-1467
OpenAlex ID: A5085746103
Effects of Reverse Transcriptase Inhibitors on Proliferation, Apoptosis, and Migration in Breast Carcinoma Cells
2020 · Zülal Atlı Şekeroğlu, Vedat Şekeroğlu, et al. · International Journal of Toxicology · 23
Effects of trimetazidine on anticancer activity and toxicity of abraxane in MCF-7 breast cancer cells
2022 · Zülal Atlı Şekeroğlu, Emre Kendigelen, et al. · RENDICONTI LINCEI · 9
Polypharmacy in Outpatients with Bipolar Disorder: Associated Factors and Treatment Characteristics in Türkiye
2023 · Neriman ARAS, Fatma ÇOKER, et al. · Sakarya Medical Journal · 1
PDF
Reporter-coded rechallenge as a selected documentation stratum: analysis repository for a bias-diagnostic FAERS study
2026 · KÜÇÜK YILMAZ, NİHAN, BEŞİKÇİOĞLU, HÜSEYİN ERDİNÇ, et al. · Zenodo (CERN European Organization for Nuclear Research)
Label-Informed Active-Comparator Disproportionality Analysis of Vimseltinib Versus Pexidartinib in Target-Drug-Restricted FAERS Reports
2026 · KÜÇÜK YILMAZ, NİHAN · Zenodo (CERN European Organization for Nuclear Research)
Dasatinib as a Repurposing Candidate for Alzheimer’s Disease: An Integrated In Silico Network Pharmacology and Molecular Docking Study
2026 · Nihan Küçük Yılmaz · Trends in pharmacy.
PDF
Rechallenge-coded hepatic reporting enrichment in FAERS: a bias-diagnostic disproportionality analysis of oral targeted anticancer agents
2026 · KÜÇÜK YILMAZ, NİHAN · Zenodo (CERN European Organization for Nuclear Research)
Rechallenge-coded hepatic reporting enrichment in FAERS: a bias-diagnostic disproportionality analysis of oral targeted anticancer agents
2026 · KÜÇÜK YILMAZ, NİHAN · Zenodo (CERN European Organization for Nuclear Research)
Effects of 3-Month Vitamin D 3 Supplementation on Motor and Non-Motor Symptoms in Parkinson’s Disease: A Single-Arm Interventional Study
2026 · Fatma Oznur Afacan, Serdar Aykac, et al. · Clinical Gerontologist
Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis
2026 · Nihan Küçük Yılmaz, Veysel Baskın · Investigational New Drugs
PDF
Evaluation of GSTP1 Inhibition Potentials and Pharmacokinetic Properties of Stigmasterol, Sesamin, and Pinosylvin
2025 · Nihan Küçük, Mehmet Özcan · Hitit Medical Journal
PDF
Nigella Sativa and Brain
2024 · Nihan Kucuk, Veysel Baskin
Works count: 12
Citation count: 33
H-index: 2
I10-index: 1
Year
Topic
Type